Impact Therapeutics

Executive Summary

Impact Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, dedicated to developing targeted small molecule anti-cancer therapies, with a primary focus on DNA damage response (DDR) pathways. Its lead asset, senaparib (IMP4297), is a PARP inhibitor currently in Phase 3 clinical trials for ovarian cancer. The company has built a robust pipeline targeting novel oncology mechanisms and is leveraging its expertise in DDR biology to address unmet medical needs in cancer treatment. With over a decade of operations and a team of 200-500 employees, Impact Therapeutics is positioned to become a key player in the oncology space, particularly in the Chinese market where PARP inhibitors have shown significant promise. The company's late-stage program and focus on precision medicine underscore its potential to deliver the next wave of targeted cancer therapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data for Senaparib (IMP4297) in Ovarian Cancer70% success
• Q1 2027NDA Submission for Senaparib in China65% success
• H2 2026Strategic Partnership or Licensing Deal for Ex-China Rights50% success